Sanofi Targets 18 Drug Launches From 2012 To 2015
This article was originally published in The Pink Sheet Daily
Management highlighted several near-term product launch opportunities during a year-end sales and earnings call in an attempt to assure investors business goes on after Plavix, Avapro patent expirations.
You may also be interested in...
Europe’s top drug advisory panel, CHMP, gave backing to Novo Nordisk’s new long-acting insulin analog as well as to new therapies from Astellas and Savient for urinary incontinence and severe gout.
Several new drugs for multiple sclerosis could launch within the next two years, but amid escalating drug costs, payors are taking a harder look at the therapeutic category. New drugs will face increasing reimbursement hurdles, as payors implement the first prior authorization and step therapy protocols and look for ways to implement further cost reductions.
Sanofi Sees Strength In Regional Volatility, GSK Lowers Revenue Target After Price Cuts – Emerging Market Earnings Roundup (Part 4)
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets.